Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Maximum (Peak) Plasma Drug Concentration (Cmax) of REC-4881

  Measured over: Day 1 through Day 43

• Part 1: Time to Reach Cmax (Tmax) of REC-4881

  Measured over: Day 1 through Day 43

• Part 1: Area Under the Plasma Concentration-time Curve (AUC) of REC-4881

  Measured over: Day 1 through Day 43

• Part 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  Measured over: Day 1 through up to Week 37

• Part 2: Number of Participants With Dose-limiting Toxicities (DLTs)

  Measured over: First 28 days of treatment

• Part 2: Number of Participants Who Discontinued Treatment

  Measured over: Day 1 through up to Week 37

• Part 2: Number of Participants With Dose Modification Due to Toxicity

  Measured over: Day 1 through up to Week 37

• Part 2: Percent Change From Baseline in Polyp Burden

  Measured over: Baseline, up to Week 37

Changes Tremor has spotted